Article
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Mar 2018
Michel Pierre, Boige Valerie, Andre Thierry, Aparicio Thomas, Bachet Jean Baptiste, Dahan Laetitia, Guimbaud Rosine, Lepage Côme, Manfredi Sylvain, Tougeron David, Taieb Julien, Selves Janick, Le Malicot Karine, Di Fiore Frederic, Maillard Emilie
Abstract excerpt
Oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk stage II. Two recent retrospective studies strongly suggested that low-dose aspirin used (100 mg/d) after surgical resection of colorectal cancer with a PIK3CA mutation could act as a targeted therapy with a major protective effect on the risk of recurrence. We propose a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.